Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastroesophageal Junction Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Gastric Cancer (780
)
Gastroesophageal Cancer (41
)
Gastric Adenocarcinoma (40
)
Gastric Cancer (780
)
Gastroesophageal Cancer (41
)
Gastric Adenocarcinoma (40
)
›
Associations
(185)
News
Trials
VERI cancer hierarchy
Reset Filters
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
zolbetuximab-clzb
Sensitive: A1 - Approval
Precision Medicine Online - 3 weeks (New A1)
zolbetuximab-clzb
Sensitive
:
A1
Precision Medicine Online - 3wk
zolbetuximab-clzb
Sensitive: A1 - Approval
Precision Medicine Online - 3 weeks
zolbetuximab-clzb
Sensitive
:
A1
Precision Medicine Online - 3 weeks - (New A1)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
Sensitive: A1 - Approval
Sensitive
:
A1
Sensitive: A1 - Approval
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-strf
Sensitive: A1 - Approval
trastuzumab-strf
Sensitive
:
A1
trastuzumab-strf
Sensitive: A1 - Approval
trastuzumab-strf
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
disitamab vedotin
Sensitive: A1 - Approval
disitamab vedotin
Sensitive
:
A1
disitamab vedotin
Sensitive: A1 - Approval
disitamab vedotin
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
tislelizumab-jsgr
Sensitive: A1 - Approval
tislelizumab-jsgr
Sensitive
:
A1
HER-2 positive + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 positive + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-strf
Sensitive: A1 - Approval
trastuzumab-strf
Sensitive
:
A1
trastuzumab-strf
Sensitive: A1 - Approval
trastuzumab-strf
Sensitive
:
A1
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login